Review



cd2ap human pre designed sirna  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress cd2ap human pre designed sirna
    Analysis of proteomics data in the CPTAC database. (A) Comparison of the protein levels between normal (green) and tumour (red) samples. (B) Kaplan–Meier curve for each protein. (C) Pan-cancer analysis for <t>CD2AP</t> (green: normal tissue, red: cancer tissue). (D) Relationship between CD2AP protein level and immune infiltration in pan-cancer.
    Cd2ap Human Pre Designed Sirna, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd2ap human pre designed sirna/product/MedChemExpress
    Average 94 stars, based on 6 article reviews
    cd2ap human pre designed sirna - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma"

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2025.1726531

    Analysis of proteomics data in the CPTAC database. (A) Comparison of the protein levels between normal (green) and tumour (red) samples. (B) Kaplan–Meier curve for each protein. (C) Pan-cancer analysis for CD2AP (green: normal tissue, red: cancer tissue). (D) Relationship between CD2AP protein level and immune infiltration in pan-cancer.
    Figure Legend Snippet: Analysis of proteomics data in the CPTAC database. (A) Comparison of the protein levels between normal (green) and tumour (red) samples. (B) Kaplan–Meier curve for each protein. (C) Pan-cancer analysis for CD2AP (green: normal tissue, red: cancer tissue). (D) Relationship between CD2AP protein level and immune infiltration in pan-cancer.

    Techniques Used: Comparison

    TMB and immune cell analysis. (A) The top 20 mutated genes in the CD2AP -low subgroup. (B) The top 20 mutated genes in the CD2AP -high subgroup. In both panels, the genes are ordered from top to bottom by their mutation frequency. The most frequently mutated genes in the entire cohort are TP53 and TTN. (C) The infiltration fraction for each immune cell between the CD2AP -low(blue) and the CD2AP -high(red) subgroups. (D) The relationship between CD2AP copy number variation and the infiltration level of immune cells. *, P <0.05**, P <0.01; ***, P <0.001.
    Figure Legend Snippet: TMB and immune cell analysis. (A) The top 20 mutated genes in the CD2AP -low subgroup. (B) The top 20 mutated genes in the CD2AP -high subgroup. In both panels, the genes are ordered from top to bottom by their mutation frequency. The most frequently mutated genes in the entire cohort are TP53 and TTN. (C) The infiltration fraction for each immune cell between the CD2AP -low(blue) and the CD2AP -high(red) subgroups. (D) The relationship between CD2AP copy number variation and the infiltration level of immune cells. *, P <0.05**, P <0.01; ***, P <0.001.

    Techniques Used: Cell Analysis, Mutagenesis

    Pathway enrichment analysis. (A) GO analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (B) KEGG analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (C) GSEA analysis for CD2AP -low and CD2AP -high subgroups.
    Figure Legend Snippet: Pathway enrichment analysis. (A) GO analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (B) KEGG analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (C) GSEA analysis for CD2AP -low and CD2AP -high subgroups.

    Techniques Used:

    Single-cell and IHC analysis. (A) Single-cell analysis for GSE99254 . (B) Healthy lung tissue (Patient ID: 2101) staining with CD2AP. (C) LUAD tissue (Patient ID: 2438) staining with CD2AP.
    Figure Legend Snippet: Single-cell and IHC analysis. (A) Single-cell analysis for GSE99254 . (B) Healthy lung tissue (Patient ID: 2101) staining with CD2AP. (C) LUAD tissue (Patient ID: 2438) staining with CD2AP.

    Techniques Used: Single-cell Analysis, Staining

    Exploration of CD2AP functions. (A) CD2AP gene expression across all cell types; (B) CD2AP gene expression in monocyte subtypes; (C) Expression distribution of CD2AP in cancer cells and monocytes; (D) Cellular interaction network of CD2AP + cancer cells LUAD; (E) Dot plot for the enrichment of ligand-receptor pathways; (F) KEGG pathway enrichment analysis for CD2AP + and CD2AP - monocytes.
    Figure Legend Snippet: Exploration of CD2AP functions. (A) CD2AP gene expression across all cell types; (B) CD2AP gene expression in monocyte subtypes; (C) Expression distribution of CD2AP in cancer cells and monocytes; (D) Cellular interaction network of CD2AP + cancer cells LUAD; (E) Dot plot for the enrichment of ligand-receptor pathways; (F) KEGG pathway enrichment analysis for CD2AP + and CD2AP - monocytes.

    Techniques Used: Gene Expression, Expressing

    Drug sensitivity analysis and molecular docking. (A) Venn plot indicating the potential targeted compounds. (B) The structures of CD2AP. (C) Molecular docking between afatinib and CD2AP. (D) Molecular docking between dasatinib and CD2AP.
    Figure Legend Snippet: Drug sensitivity analysis and molecular docking. (A) Venn plot indicating the potential targeted compounds. (B) The structures of CD2AP. (C) Molecular docking between afatinib and CD2AP. (D) Molecular docking between dasatinib and CD2AP.

    Techniques Used:

    Histological experiments to validate the expression of CD2AP. (A) Validation of CD2AP expression in cancer and adjacent tissues by immunofluorescence (n=3 biologically independent samples); (B) Determine CD2AP protein levels using Western blot analysis; (C) Statistical chart for WB, data are presented as mean ± SD (n=5 biologically independent samples). * P < 0.05; (D) Results of rt-qPCR for 5 controls vs. 5 LUADs, data are presented as mean ± SD (n=5 biologically independent samples). ** P < 0.01.
    Figure Legend Snippet: Histological experiments to validate the expression of CD2AP. (A) Validation of CD2AP expression in cancer and adjacent tissues by immunofluorescence (n=3 biologically independent samples); (B) Determine CD2AP protein levels using Western blot analysis; (C) Statistical chart for WB, data are presented as mean ± SD (n=5 biologically independent samples). * P < 0.05; (D) Results of rt-qPCR for 5 controls vs. 5 LUADs, data are presented as mean ± SD (n=5 biologically independent samples). ** P < 0.01.

    Techniques Used: Expressing, Biomarker Discovery, Immunofluorescence, Western Blot, Quantitative RT-PCR

    Cell experiments to validate the function of CD2AP. (A) WB to show the knockdown efficiency of CD2AP; (B) Statistical chart for WB, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01; (C) Proliferative capacity of A549 cells by CCK-8 assay, data are presented as mean ± SD (n=3 technical replicates per group, representative of three independent experiments); (D) Cell migration capabilities by transwell; (E) Statistical chart for transwell counts, data are presented as mean ± SD (n=3 biologically independent samples). **** P < 0.0001; (F) Cell migration capabilities by wound healing assays; (G) Statistical chart for wound healing assays, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01.
    Figure Legend Snippet: Cell experiments to validate the function of CD2AP. (A) WB to show the knockdown efficiency of CD2AP; (B) Statistical chart for WB, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01; (C) Proliferative capacity of A549 cells by CCK-8 assay, data are presented as mean ± SD (n=3 technical replicates per group, representative of three independent experiments); (D) Cell migration capabilities by transwell; (E) Statistical chart for transwell counts, data are presented as mean ± SD (n=3 biologically independent samples). **** P < 0.0001; (F) Cell migration capabilities by wound healing assays; (G) Statistical chart for wound healing assays, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01.

    Techniques Used: Knockdown, CCK-8 Assay, Migration



    Similar Products

    cd2ap human pre designed sirna  (MedChemExpress)
    94
    MedChemExpress cd2ap human pre designed sirna
    Analysis of proteomics data in the CPTAC database. (A) Comparison of the protein levels between normal (green) and tumour (red) samples. (B) Kaplan–Meier curve for each protein. (C) Pan-cancer analysis for <t>CD2AP</t> (green: normal tissue, red: cancer tissue). (D) Relationship between CD2AP protein level and immune infiltration in pan-cancer.
    Cd2ap Human Pre Designed Sirna, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd2ap human pre designed sirna/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    cd2ap human pre designed sirna - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Analysis of proteomics data in the CPTAC database. (A) Comparison of the protein levels between normal (green) and tumour (red) samples. (B) Kaplan–Meier curve for each protein. (C) Pan-cancer analysis for CD2AP (green: normal tissue, red: cancer tissue). (D) Relationship between CD2AP protein level and immune infiltration in pan-cancer.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: Analysis of proteomics data in the CPTAC database. (A) Comparison of the protein levels between normal (green) and tumour (red) samples. (B) Kaplan–Meier curve for each protein. (C) Pan-cancer analysis for CD2AP (green: normal tissue, red: cancer tissue). (D) Relationship between CD2AP protein level and immune infiltration in pan-cancer.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques: Comparison

    TMB and immune cell analysis. (A) The top 20 mutated genes in the CD2AP -low subgroup. (B) The top 20 mutated genes in the CD2AP -high subgroup. In both panels, the genes are ordered from top to bottom by their mutation frequency. The most frequently mutated genes in the entire cohort are TP53 and TTN. (C) The infiltration fraction for each immune cell between the CD2AP -low(blue) and the CD2AP -high(red) subgroups. (D) The relationship between CD2AP copy number variation and the infiltration level of immune cells. *, P <0.05**, P <0.01; ***, P <0.001.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: TMB and immune cell analysis. (A) The top 20 mutated genes in the CD2AP -low subgroup. (B) The top 20 mutated genes in the CD2AP -high subgroup. In both panels, the genes are ordered from top to bottom by their mutation frequency. The most frequently mutated genes in the entire cohort are TP53 and TTN. (C) The infiltration fraction for each immune cell between the CD2AP -low(blue) and the CD2AP -high(red) subgroups. (D) The relationship between CD2AP copy number variation and the infiltration level of immune cells. *, P <0.05**, P <0.01; ***, P <0.001.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques: Cell Analysis, Mutagenesis

    Pathway enrichment analysis. (A) GO analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (B) KEGG analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (C) GSEA analysis for CD2AP -low and CD2AP -high subgroups.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: Pathway enrichment analysis. (A) GO analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (B) KEGG analysis for the DEGs between the CD2AP -low and CD2AP -high subgroups. (C) GSEA analysis for CD2AP -low and CD2AP -high subgroups.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques:

    Single-cell and IHC analysis. (A) Single-cell analysis for GSE99254 . (B) Healthy lung tissue (Patient ID: 2101) staining with CD2AP. (C) LUAD tissue (Patient ID: 2438) staining with CD2AP.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: Single-cell and IHC analysis. (A) Single-cell analysis for GSE99254 . (B) Healthy lung tissue (Patient ID: 2101) staining with CD2AP. (C) LUAD tissue (Patient ID: 2438) staining with CD2AP.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques: Single-cell Analysis, Staining

    Exploration of CD2AP functions. (A) CD2AP gene expression across all cell types; (B) CD2AP gene expression in monocyte subtypes; (C) Expression distribution of CD2AP in cancer cells and monocytes; (D) Cellular interaction network of CD2AP + cancer cells LUAD; (E) Dot plot for the enrichment of ligand-receptor pathways; (F) KEGG pathway enrichment analysis for CD2AP + and CD2AP - monocytes.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: Exploration of CD2AP functions. (A) CD2AP gene expression across all cell types; (B) CD2AP gene expression in monocyte subtypes; (C) Expression distribution of CD2AP in cancer cells and monocytes; (D) Cellular interaction network of CD2AP + cancer cells LUAD; (E) Dot plot for the enrichment of ligand-receptor pathways; (F) KEGG pathway enrichment analysis for CD2AP + and CD2AP - monocytes.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques: Gene Expression, Expressing

    Drug sensitivity analysis and molecular docking. (A) Venn plot indicating the potential targeted compounds. (B) The structures of CD2AP. (C) Molecular docking between afatinib and CD2AP. (D) Molecular docking between dasatinib and CD2AP.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: Drug sensitivity analysis and molecular docking. (A) Venn plot indicating the potential targeted compounds. (B) The structures of CD2AP. (C) Molecular docking between afatinib and CD2AP. (D) Molecular docking between dasatinib and CD2AP.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques:

    Histological experiments to validate the expression of CD2AP. (A) Validation of CD2AP expression in cancer and adjacent tissues by immunofluorescence (n=3 biologically independent samples); (B) Determine CD2AP protein levels using Western blot analysis; (C) Statistical chart for WB, data are presented as mean ± SD (n=5 biologically independent samples). * P < 0.05; (D) Results of rt-qPCR for 5 controls vs. 5 LUADs, data are presented as mean ± SD (n=5 biologically independent samples). ** P < 0.01.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: Histological experiments to validate the expression of CD2AP. (A) Validation of CD2AP expression in cancer and adjacent tissues by immunofluorescence (n=3 biologically independent samples); (B) Determine CD2AP protein levels using Western blot analysis; (C) Statistical chart for WB, data are presented as mean ± SD (n=5 biologically independent samples). * P < 0.05; (D) Results of rt-qPCR for 5 controls vs. 5 LUADs, data are presented as mean ± SD (n=5 biologically independent samples). ** P < 0.01.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques: Expressing, Biomarker Discovery, Immunofluorescence, Western Blot, Quantitative RT-PCR

    Cell experiments to validate the function of CD2AP. (A) WB to show the knockdown efficiency of CD2AP; (B) Statistical chart for WB, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01; (C) Proliferative capacity of A549 cells by CCK-8 assay, data are presented as mean ± SD (n=3 technical replicates per group, representative of three independent experiments); (D) Cell migration capabilities by transwell; (E) Statistical chart for transwell counts, data are presented as mean ± SD (n=3 biologically independent samples). **** P < 0.0001; (F) Cell migration capabilities by wound healing assays; (G) Statistical chart for wound healing assays, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01.

    Journal: Frontiers in Immunology

    Article Title: Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma

    doi: 10.3389/fimmu.2025.1726531

    Figure Lengend Snippet: Cell experiments to validate the function of CD2AP. (A) WB to show the knockdown efficiency of CD2AP; (B) Statistical chart for WB, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01; (C) Proliferative capacity of A549 cells by CCK-8 assay, data are presented as mean ± SD (n=3 technical replicates per group, representative of three independent experiments); (D) Cell migration capabilities by transwell; (E) Statistical chart for transwell counts, data are presented as mean ± SD (n=3 biologically independent samples). **** P < 0.0001; (F) Cell migration capabilities by wound healing assays; (G) Statistical chart for wound healing assays, data are presented as mean ± SD (n=3 biologically independent samples). ** P < 0.01.

    Article Snippet: CD2AP Human Pre-designed siRNA was acquired from MedChemExpress (MCE).

    Techniques: Knockdown, CCK-8 Assay, Migration